NASDAQ:AKRO

Akero Therapeutics - AKRO Stock Forecast, Price & News

$37.45

-2.39 (-6.00%)

(As of 03/24/2023 08:50 PM ET)

Add

Compare

Today's Range: $37.40
▼
$39.82
50-Day Range: $37.27
▼
$50.24
52-Week Range: $7.52
▼
$54.88

Volume: 1.07 million shs
Average Volume: 596,904 shs
Market Capitalization: $1.76 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $52.40

Institutional Ownership

Akero Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 39.9% Upside
$52.40 Price Target
Short Interest: Healthy
7.26% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: 0.71
Based on 14 Articles This Week
Insider Trading: Selling Shares
$5.16 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.95) to ($3.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

217th out of 995 stocks

Pharmaceutical Preparations Industry

88th out of 482 stocks

3.5

Analyst's Opinion

Consensus Rating
Akero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $52.40, Akero Therapeutics has a forecasted upside of 39.9% from its current price of $37.45.
Amount of Analyst Coverage
Akero Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
7.26% of the outstanding shares of Akero Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Akero Therapeutics has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Akero Therapeutics has recently decreased by 5.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Akero Therapeutics does not currently pay a dividend.
Dividend Growth
Akero Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Akero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Akero Therapeutics is -0.75.

2.6

News and Social Media Coverage

News Sentiment
Akero Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Akero Therapeutics this week, compared to 2 articles on an average week.
MarketBeat Follows
3 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,161,061.00 in company stock.
Percentage Held by Insiders
10.38% of the stock of Akero Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.76% of the stock of Akero Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Akero Therapeutics are expected to decrease in the coming year, from ($2.95) to ($3.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akero Therapeutics is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akero Therapeutics is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akero Therapeutics has a P/B Ratio of 7.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Akero Therapeutics (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKRO Stock News Headlines

March 24, 2023 | americanbankingnews.com

Akero Therapeutics (NASDAQ:AKRO) Sees Unusually-High Trading Volume Following Analyst Upgrade

March 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Akero Therapeutics (AKRO)

March 27, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 23, 2023 | americanbankingnews.com

Canaccord Genuity Group Increases Akero Therapeutics (NASDAQ:AKRO) Price Target to $58.00

March 22, 2023 | finance.yahoo.com

Top 1% Biotech 89bio Scores 29% Gain As Battle In Liver Disease Heats Up

March 22, 2023 | finance.yahoo.com

89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease

March 22, 2023 | americanbankingnews.com

Akero Therapeutics (NASDAQ:AKRO) Trading Down 4.3%

March 22, 2023 | americanbankingnews.com

Akero Therapeutics, Inc. (NASDAQ:AKRO) to Post Q1 2023 Earnings of ($0.71) Per Share, HC Wainwright Forecasts

March 27, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

March 21, 2023 | benzinga.com

Akero Therapeutics Stock (NASDAQ:AKRO), Guidance and Forecast

March 20, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Akero Therapeutics (AKRO)

March 17, 2023 | finance.yahoo.com

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

March 14, 2023 | seekingalpha.com

AKRO Akero Therapeutics, Inc.

March 10, 2023 | theglobeandmail.com

Markets Today: Stocks Rally as Concern Eases About Aggressive Fed

February 11, 2023 | reuters.com

AKRO.O

January 27, 2023 | 247wallst.com

First Look Analysts Research Calls for Friday, January 27

January 10, 2023 | finance.yahoo.com

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

January 4, 2023 | finance.yahoo.com

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 22, 2022 | finance.yahoo.com

Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program

December 21, 2022 | finance.yahoo.com

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones

December 20, 2022 | finance.yahoo.com

Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study

December 8, 2022 | finance.yahoo.com

Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH

November 17, 2022 | nasdaq.com

Noteworthy Thursday Option Activity: ETSY, AKRO, MAN

November 13, 2022 | finance.yahoo.com

Akero Therapeutics, Inc.'s (NASDAQ:AKRO) large institutional owners must be happy as stock continues to impress, up 5.6% over the past week

November 10, 2022 | finance.yahoo.com

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

November 8, 2022 | finance.yahoo.com

Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?

November 7, 2022 | benzinga.com

Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD's The Liver Meeting® 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKRO Company Calendar

Last Earnings: 11/12/2021
Today: 3/26/2023
Next Earnings (Estimated): 5/05/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKRO
CUSIP: N/A
CIK: 1744659
Web: www.akerotx.com
Phone: (650) 487-6488
Fax: N/A
Employees: 33
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $52.40
High Stock Price Forecast: $65.00
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +39.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -46.44%
Return on Assets: -41.06%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 18.61
Quick Ratio: 14.97

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.85 per share
Price / Book: 7.72

Miscellaneous

Outstanding Shares: 46,970,000
Free Float: 42,095,000
Market Cap: $1.76 billion
Optionable: Not Optionable
Beta: -0.91

Key Executives

Andrew Cheng
President, Chief Executive Officer & Director

Jonathan Young
Chief Operating Officer & Executive Vice President

William R. White
CFO, Treasurer, EVP & Head-Corporate Development

Timothy Rolph
Chief Scientific Officer

Reshma Shringarpure
Vice President-Clinical Research & Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKRO Stock - Frequently Asked Questions

Should I buy or sell Akero Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings or view top-rated stocks.
What is Akero Therapeutics' stock price forecast for 2023?: 4 brokerages have issued 1 year price targets for Akero Therapeutics' shares. Their AKRO share price forecasts range from $25.00 to $65.00. On average, they expect the company's stock price to reach $52.40 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price.
View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts.
How have AKRO shares performed in 2023?: Akero Therapeutics' stock was trading at $54.80 at the start of the year. Since then, AKRO stock has decreased by 31.7% and is now trading at $37.45.
View the best growth stocks for 2023 here.
When is Akero Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our AKRO earnings forecast.
How were Akero Therapeutics' earnings last quarter?: Akero Therapeutics, Inc. (NASDAQ:AKRO) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.91) by $0.21.
What ETFs hold Akero Therapeutics' stock?: ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Invesco DWA SmallCap Momentum ETF (DWAS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC).

What other stocks do shareholders of Akero Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).
When did Akero Therapeutics IPO?: (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager.
What is Akero Therapeutics' stock symbol?: Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."
Who are Akero Therapeutics' major shareholders?: Akero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Avidity Partners Management LP (8.18%), Skorpios Trust (7.00%), Alkeon Capital Management LLC (6.94%), Price T Rowe Associates Inc. MD (5.13%), Marshall Wace LLP (3.22%) and Geode Capital Management LLC (1.35%). Insiders that own company stock include Andrew Cheng, Apple Tree Partners Iv, LP, Catriona Yale, Global Strategic Fund I Venbio, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph and William Richard White.
View institutional ownership trends.
How do I buy shares of Akero Therapeutics?: Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Akero Therapeutics' stock price today?: One share of AKRO stock can currently be purchased for approximately $37.45.
How much money does Akero Therapeutics make?: Akero Therapeutics (NASDAQ:AKRO) has a market capitalization of $1.76 billion. The company earns $-112,030,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.
How can I contact Akero Therapeutics?: Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.akerotx.com. The company can be reached via phone at (650) 487-6488 or via email at akero@sternir.com.

This page (NASDAQ:AKRO) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Akero Therapeutics - AKRO Stock Forecast, Price & News

Akero Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Akero Therapeutics (NASDAQ:AKRO) Stock

AKRO Stock News Headlines

AKRO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AKRO Stock - Frequently Asked Questions

Overall MarketRank^™